Otsuka and ShapeTX to develop gene therapies for eye diseases
08 Sep 2023
Gene TherapyLicense out/in
Preview
Source: Pharmaceutical Technology
The companies will develop gene therapies for ocular diseases under the new deal. Credit: elenavolf / Shutterstock.com.
Preview
Source: Pharmaceutical Technology
Otsuka Pharmaceutical has entered a multi-target partnership with ShapeTX for the development of new adeno-associated viruses (AAV) gene therapies to treat ocular diseases.
The parties will focus on developing intravitreally delivered AAVs.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Gene Therapy to Target BCMA for Relapsed and Refractory Multiple Myeloma GlobalData
Preview
Source: Pharmaceutical Technology
View all
The AAVid capsid discovery platform and transgene engineering technology of ShapeTX will be combined with the capabilities of Otsuka in genetic payload design and ophthalmology.
Otsuka will also make developmental, regulatory and sales-based milestone payments totalling more than $1.5bn.
Based on potential sales of products developed by the partnership, ShapeTX will also receive tiered royalty payments.
ShapeTX’s artificial intelligence (AI)-powered AAVid platform merges throughput screening of numerous AAV variants and machine learning to detect new AAV capsids for direct-to-NHP in vivo selection to enhance clinical translation.
The collaboration offers options to include other targets and tissue types in the future.
Otsuka Pharmaceutical Osaka Research Center for Drug Discovery executive director and head Toshiki Sudo stated: “Our recent research activities have led to the identification of target molecules and antibodies for specific ocular diseases of interest with high unmet medical needs.
“Our collaboration with ShapeTX aims to enable the delivery of vectorised antibody drugs in combination with AAV, in order to target specific disease cell types in the eye and provide a once-in-a-lifetime and curative administration with stable lifetime expression.
“This holds the potential to become dramatically beneficial to patients who have suffered from specific chronic ocular diseases.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.